Venous thromboembolism, that consists of the interrelated conditions deep-vein thrombosis
and pulmonary embolism, is an under-appreciated vascular disease. In Western regions …

Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background Hereditary and acquired thrombophilia are risk factors for venous
thromboembolism (VTE). Whether testing helps guide management decisions is …

Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …

Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent)
venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a …

This position paper provides a comprehensive guide for optimal follow-up of patients with
acute pulmonary embolism (PE), covering multiple relevant aspects of patient counselling. It …

Venous thromboembolism (VTE) is the third most common cardiovascular disorder, affecting
up to 5% of the population. VTE commonly manifests as lower-extremity deep venous …

Background: A small randomized controlled trial suggested that dabigatran may be as
effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to …

Background Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight
heparin for treating cancer-associated VTE. Research Question Is rivaroxaban as efficient …